Skip to main content
Top
Published in: International Urology and Nephrology 4/2007

01-12-2007 | Original Article

Prostate biopsy in subjects with abnormal transrectal ultrasonography but normal digital examination findings and prostate-specific antigen levels

Authors: Hong Bang Shim, Sang Eun Lee, Hyoung Keun Park, Ja Hyeon Ku

Published in: International Urology and Nephrology | Issue 4/2007

Login to get access

Abstract

Aim

The aim of the present study was to evaluate the value of transrectal ultrasonography (TRUS) for prostate cancer diagnosis in men with no other indication for biopsy, such as an abnormal digital rectal examination or abnormally high prostate-specific antigen (PSA) levels.

Materials and methods

The study cohort contained a total of 104 men aged 41–78 years (median 62.5 years) who had suspicious findings on TRUS. The median prostate volume of the patients was 33.0 ml (range 15.0–90.9) and the serum PSA ranged from 0.2 to 4.0 ng/ml (median 2.5 ng/ml).

Results

Of 104 men, 12 (11.5%) were diagnosed with prostate cancer on initial biopsy. The positive predictive value (PPV) was 3.7% for PSA 0.1–1.0 ng/ml, 4.8% for PSA 1.1–2.0 ng/ml, 16.7% for PSA 2.1–3.0 ng/ml and 18.4% for PSA 3.1–4.0 ng/ml. The PPV for cancer with Gleason score 7 or higher was 0.0%, 0.0%, 16.7% and 7.9%, respectively. No statistically significant differences in patient characteristics and biopsy results were found between patients who received only systemic biopsy and those who received systemic plus lesion-directed biopsies.

Conclusion

The results of this study do not provide a rationale to recommend the additional use of lesion-directed biopsy in patients with suspicious lesions at TRUS but with no other indication for biopsy. Furthermore, our data raise the question of whether serum PSA levels lower than 4.0 ng/ml should be considered normal in Asian men.
Literature
1.
go back to reference Catalona WJ, Richie JP, de Kernion JB et al (1994) Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: receiver operating characteristic curves. J Urol 152:2031–2036PubMed Catalona WJ, Richie JP, de Kernion JB et al (1994) Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: receiver operating characteristic curves. J Urol 152:2031–2036PubMed
2.
go back to reference Cooner WH, Mosley BR, Rutherford CL Jr et al (1990) Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. J Urol 143:1146–1152PubMed Cooner WH, Mosley BR, Rutherford CL Jr et al (1990) Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. J Urol 143:1146–1152PubMed
3.
go back to reference Ku JH (2006) Race-specific reference ranges of serum prostate-specific antigen levels in countries with a low incidence of prostate cancer. BJU Int 97:69–72PubMedCrossRef Ku JH (2006) Race-specific reference ranges of serum prostate-specific antigen levels in countries with a low incidence of prostate cancer. BJU Int 97:69–72PubMedCrossRef
4.
go back to reference Kim JW, Lee HY, Hong SJ et al (2004) Can a 12 core prostate biopsy increase the detection rate of prostate cancer versus 6 core?: a prospective randomized study in Korea. Yonsei Med J 45:671–675PubMed Kim JW, Lee HY, Hong SJ et al (2004) Can a 12 core prostate biopsy increase the detection rate of prostate cancer versus 6 core?: a prospective randomized study in Korea. Yonsei Med J 45:671–675PubMed
5.
go back to reference Yang WJ, Lee DH, Chung BH et al (2006) Detection rate of prostate cancer on biopsy according to serum prostate-specific antigen in Korean men: a multicenter study. Urology 67:333–336PubMedCrossRef Yang WJ, Lee DH, Chung BH et al (2006) Detection rate of prostate cancer on biopsy according to serum prostate-specific antigen in Korean men: a multicenter study. Urology 67:333–336PubMedCrossRef
6.
go back to reference Egawa S, Matsumoto K, Yoshida K et al (1998) Results of transrectal ultrasound-guided biopsies and clinical significance of Japanese prostate cancer. Jpn J Clin Oncol 28:666–672PubMedCrossRef Egawa S, Matsumoto K, Yoshida K et al (1998) Results of transrectal ultrasound-guided biopsies and clinical significance of Japanese prostate cancer. Jpn J Clin Oncol 28:666–672PubMedCrossRef
7.
go back to reference Thompson IM, Pauler DK, Goodman PJ et al (2004) Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 350:2239–2246PubMedCrossRef Thompson IM, Pauler DK, Goodman PJ et al (2004) Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 350:2239–2246PubMedCrossRef
8.
go back to reference Brawn PN, Speights VO, Kuhl D et al (1991) Prostate-specific antigen levels from completely sectioned, clinically benign, whole prostates. Cancer 68:1592–1599PubMedCrossRef Brawn PN, Speights VO, Kuhl D et al (1991) Prostate-specific antigen levels from completely sectioned, clinically benign, whole prostates. Cancer 68:1592–1599PubMedCrossRef
9.
go back to reference Carter HB, Epstein JI, Chan DW et al (1997) Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer. JAMA 277:1456–1460PubMedCrossRef Carter HB, Epstein JI, Chan DW et al (1997) Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer. JAMA 277:1456–1460PubMedCrossRef
10.
go back to reference Krumholtz JS, Carvalhal GF, Ramos CG et al (2002) Prostate-specific antigen cutoff of 2.6 ng/mL for prostate cancer screening is associated with favorable pathologic tumor features. Urology 60:469–473PubMedCrossRef Krumholtz JS, Carvalhal GF, Ramos CG et al (2002) Prostate-specific antigen cutoff of 2.6 ng/mL for prostate cancer screening is associated with favorable pathologic tumor features. Urology 60:469–473PubMedCrossRef
11.
go back to reference Catalona WJ, Smith DS, Ornstein DK (1997) Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA 277:1452–1455PubMedCrossRef Catalona WJ, Smith DS, Ornstein DK (1997) Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA 277:1452–1455PubMedCrossRef
12.
go back to reference Schroder FH, van der Cruijsen-koeter I, de Koning HJ et al (2000) Prostate cancer detection at low prostate specific antigen. J Urol 163:806–812PubMedCrossRef Schroder FH, van der Cruijsen-koeter I, de Koning HJ et al (2000) Prostate cancer detection at low prostate specific antigen. J Urol 163:806–812PubMedCrossRef
13.
go back to reference Recker F, Kwiatkowski MK, Huber A et al (2001) Prospective detection of clinically relevant prostate cancer in the prostate specific antigen range 1 to 3 ng/ml combined with free-to-total ratio 20% or less: the Aarau experience. J Urol 166:851–855PubMedCrossRef Recker F, Kwiatkowski MK, Huber A et al (2001) Prospective detection of clinically relevant prostate cancer in the prostate specific antigen range 1 to 3 ng/ml combined with free-to-total ratio 20% or less: the Aarau experience. J Urol 166:851–855PubMedCrossRef
14.
go back to reference Sokoloff MH, Yang XJ, Fumo M et al (2004) Characterizing prostatic adenocarcinomas in men with a serum prostate specific antigen level of <4.0 ng/mL. BJU Int 93:499–502PubMedCrossRef Sokoloff MH, Yang XJ, Fumo M et al (2004) Characterizing prostatic adenocarcinomas in men with a serum prostate specific antigen level of <4.0 ng/mL. BJU Int 93:499–502PubMedCrossRef
15.
go back to reference Kokeny GP, Cerri GG, de Oliveira Cerri LM et al (2000) Correlations among prostatic biopsy results, transrectal ultrasound findings and PSA levels in diagnosing prostate adenocarcinoma. Eur J Ultrasound 12:103–113PubMedCrossRef Kokeny GP, Cerri GG, de Oliveira Cerri LM et al (2000) Correlations among prostatic biopsy results, transrectal ultrasound findings and PSA levels in diagnosing prostate adenocarcinoma. Eur J Ultrasound 12:103–113PubMedCrossRef
16.
go back to reference Imai K, Ichinose Y, Kubota Y et al (1995) Diagnostic significance of prostate specific antigen and the development of a mass screening system for prostate cancer. J Urol 154:1085–1089PubMedCrossRef Imai K, Ichinose Y, Kubota Y et al (1995) Diagnostic significance of prostate specific antigen and the development of a mass screening system for prostate cancer. J Urol 154:1085–1089PubMedCrossRef
17.
go back to reference Egawa S, Suyama K, Ohori M et al (1995) Early detection of prostate cancer. Results of a prostate specific antigen-based detection program in Japan. Cancer 76:463–472PubMedCrossRef Egawa S, Suyama K, Ohori M et al (1995) Early detection of prostate cancer. Results of a prostate specific antigen-based detection program in Japan. Cancer 76:463–472PubMedCrossRef
18.
go back to reference Loch T, Eppelmann U, Lehmann J et al (2004) Transrectal ultrasound guided biopsy of the prostate: random sextant versus biopsies of sono-morphologically suspicious lesions. World J Urol 22:357–360PubMedCrossRef Loch T, Eppelmann U, Lehmann J et al (2004) Transrectal ultrasound guided biopsy of the prostate: random sextant versus biopsies of sono-morphologically suspicious lesions. World J Urol 22:357–360PubMedCrossRef
Metadata
Title
Prostate biopsy in subjects with abnormal transrectal ultrasonography but normal digital examination findings and prostate-specific antigen levels
Authors
Hong Bang Shim
Sang Eun Lee
Hyoung Keun Park
Ja Hyeon Ku
Publication date
01-12-2007
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 4/2007
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-007-9208-8

Other articles of this Issue 4/2007

International Urology and Nephrology 4/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.